Document Classification

Section Type: RESULTS

Text: During a mean follow-up of 2. 3 years, Respimat was noninferior to HandiHaler with respect to the risk of death (Respimat at a dose of 5 g vs. HandiHaler : hazard ratio, 0. 96 ; 95 % confidence interval [CI], 0. 84 to 1. 09 ; Respimat at a dose of 2. 5 g vs. HandiHaler : hazard ratio, 1. 00 ; 95 % CI, 0. 87 to 1. 14) and not superior to HandiHaler with respect to the risk of the first exacerbation (Respimat at a dose of 5 g vs. HandiHaler : hazard ratio, 0. 98 ; 95 % CI, 0. 93 to 1. 03).